How Long Do GLP-1 Stay in Your System? Half-Life and Clearance Chart for Major GLP-1 Medications

If you stopped your weekly GLP-1 today, half of it would still be in your body a week from now. That’s not a glitch — that’s the design.

So how long do GLP-1 stay in your system before they’re truly gone? For currently marketed weekly medications — Ozempic, Wegovy, Mounjaro, Zepbound, Trulicity — the answer is roughly 25 days to 7 weeks after your last dose. Semaglutide products generally clear in about 5 weeks (Wegovy at the 2.4 mg or 7.2 mg injection or 25 mg oral dose can run 5 to 7 weeks). Tirzepatide and dulaglutide are closer to a month. Daily liraglutide (Saxenda, Victoza) clears in about 3 days. The newer oral Foundayo (orforglipron) clears in about 6 to 10 days.

Here’s the part most pages skip: “in your system” doesn’t mean “still working at full strength.” Drug levels drop fast in the first half-life, then taper. Side effects, hunger, blood sugar, and the timing for surgery or pregnancy planning each run on their own clocks — and they don’t all line up. Every clearance number below is pulled from the current FDA prescribing information on DailyMed.

When you ask “how long does it stay in my system,” you might really be asking one of four different questions:

These four timelines are why a friend, a Reddit post, a clinic blog, and your doctor can all give you a different answer to “is it out of my system yet?” — and all be technically correct, depending on what they mean by “out.”

Take a dose. Wait until your body has gotten rid of half of it. That’s one half-life. Wait another half-life and another half is gone — so 25% remains. After five of these cycles, you’re down to about 3% remaining, and pharmacologists call that “mostly cleared.”

For semaglutide, one half-life is roughly a week. So if you take a 2 mg dose on Monday, by next Monday you have about 1 mg left. The Monday after, 0.5 mg. By week 5, about 3% remains — the practical “mostly gone” mark.

Why are GLP-1s engineered to last so long? Because the natural version doesn’t. Native GLP-1, the hormone your intestine releases when you eat, gets chopped up by an enzyme called DPP-4 within minutes. Drug companies modified the molecule by changing the parts DPP-4 binds to and adding a fatty-acid chain that lets the drug latch onto albumin, the main protein in blood — which shields it from enzymes and slows clearance dramatically.

That engineering also explains why most current GLP-1s aren’t broken down by your kidneys or liver in any major way. The body clears them through proteolytic degradation — protein-chopping enzymes throughout the body — rather than the cytochrome P450 system in the liver that handles most pills, or the renal filtration that handles many other drugs. This is why semaglutide, tirzepatide, dulaglutide, and liraglutide don’t generally need dose adjustments for kidney or liver disease.

Steady state is a separate concept. When you start a weekly GLP-1, it takes about 4 to 5 weeks of weekly dosing for the amount entering your body to balance the amount leaving — at which point your blood levels stabilize. That’s why providers titrate slowly: dose escalation is partly about steady-state accumulation, not just tolerance.

Semaglutide is the active ingredient in several branded products: Ozempic injection (FDA-approved for type 2 diabetes), Wegovy injection in 2.4 mg and 7.2 mg HD strengths (approved for chronic weight management and to reduce major adverse cardiovascular events), Rybelsus tablets and Ozempic tablets (oral semaglutide for type 2 diabetes), and Wegovy tablets (oral semaglutide for weight management).

Ozempic stays in your system for about 5 weeks. The prescribing information confirms a half-life of approximately 1 week. At the maximum 2 mg weekly dose, it takes roughly 5 half-lives — 5 weeks — to reach the 97%-cleared mark.

Wegovy stays in your system for 5 to 7 weeks. The label specifies that semaglutide can remain in circulation for about 5 to 7 weeks after the last dose. The longer tail for the 2.4 mg and 7.2 mg doses reflects the higher starting concentration.

Practical math example. If your last Ozempic 2 mg injection was on October 1:

• About 50% remaining on October 8
• About 25% remaining on October 15
• About 12% on October 22
• About 6% on October 29
• About 3% on November 5 — the practical “mostly gone” date, around day 35

Missed dose rule. Ozempic injection: if you miss a dose, take it as soon as possible, as long as the next scheduled dose is at least 2 days (48 hours) away. Wegovy injection: take the missed dose if the next dose is more than 48 hours away. If there are fewer than 48 hours until your next scheduled dose, skip it and resume your regular schedule. Wegovy tablets: if you miss a dose, skip it and take the next dose the following day.

Pregnancy. The labels for Ozempic, Wegovy, and Rybelsus all recommend stopping at least 2 months before a planned pregnancy.

Mounjaro (tirzepatide) is FDA-approved for type 2 diabetes. Zepbound (tirzepatide) is FDA-approved for chronic weight management and obstructive sleep apnea.

Half-life: approximately 5 days (Mounjaro) / 5 to 6 days (Zepbound). Multiplying the upper end by five gives the practical “mostly gone” mark of about 30 days.

Practical math example. If your last Zepbound injection was October 1:

• About 50% remaining on October 6
• About 25% on October 11
• About 12% on October 16
• About 6% on October 21
• About 3% on October 26 — the practical “mostly gone” date

Missed dose rule. Mounjaro and Zepbound: if you miss a dose, take it as soon as possible if the next scheduled dose is more than 4 days away. If fewer than 4 days remain until the next dose, skip and resume the regular schedule. Do not take two doses at the same time.

Oral contraceptive interaction. The Zepbound label recommends using a non-oral contraceptive or adding a barrier method for 4 weeks after starting tirzepatide and for 4 weeks after each dose increase, due to potential for reduced oral contraceptive effectiveness from decreased gastric emptying.

Pregnancy. The tirzepatide labels (Mounjaro and Zepbound) recommend stopping at least 1 month before a planned pregnancy.

Foundayo is newer to the market than the other drugs on this page — FDA-approved on April 1, 2026 — so it shows up less in older articles. Here’s what’s on the current label.

Half-life of 29 to 49 hours. Roughly 1 to 2 days, much shorter than semaglutide’s week or tirzepatide’s 5 days. Multiplying the upper end by 5 gives the practical “mostly gone” mark of about 10 days.

Why orforglipron clears faster. Unlike semaglutide and tirzepatide, orforglipron is a small synthetic molecule, not a modified peptide. It doesn’t need to bind albumin to extend its half-life, and it can be absorbed orally without special pH-altering excipients. The trade-off is a shorter half-life — but that’s also why it’s dosed daily.

Steady state in days, not weeks. Because the half-life is shorter, steady-state concentrations are reached after about a week of daily dosing rather than the 4 to 5 weeks weekly injectables need.

Oral contraceptive interaction. The Foundayo label says oral hormonal contraceptives may be less effective. It recommends switching to a non-oral method or adding a barrier method for 30 days after starting Foundayo and for 30 days after each dose escalation.

Pregnancy. The Foundayo label says to discontinue when pregnancy is recognized.

Missed dose rule. If you miss a dose, take it as soon as possible. Don’t double up the next dose. If 7 or more consecutive doses are missed, the label directs prescribers to consider re-initiating dose escalation.

Missed dose rule. Take the missed dose only if there are at least 3 days (72 hours) until the next scheduled dose. If fewer than 3 days remain, skip and resume the regular schedule.

One thing diabetes patients should know. Blood sugar effects can change before the drug is fully gone. If you stop dulaglutide and you have type 2 diabetes, your A1C may drift upward within weeks even while measurable drug levels are still in your system, because the glucose-lowering effect tapers as concentration drops. Don’t stop a diabetes medication without a clinician-directed plan for what comes next.

Five half-lives is roughly 65 hours, or about 3 days. Compared to semaglutide’s 5-week tail, liraglutide is essentially gone in a long weekend.

Missed dose rule. Per the Victoza label, if you miss a dose, resume the once-daily regimen with the next scheduled dose — don’t take an extra dose. If more than 3 days have elapsed since the last liraglutide dose, the Victoza label directs reinitiating at 0.6 mg once daily and titrating up again. Saxenda’s label says to take your next daily dose as usual the following day after a missed dose, and to call your provider if Saxenda is missed for 3 days or more.

Pregnancy. Saxenda’s label says it should not be used during pregnancy and should be discontinued if pregnancy occurs or if you wish to become pregnant. Because the half-life is short, the washout window is days, not months — but discuss timing with your prescriber.

Byetta is the simple case. Half-life is approximately 2.4 hours. Plasma concentrations are measurable for about 10 hours after each dose. If you stop, it’s gone within roughly 24 hours.

Bydureon BCise is the exception to almost everything else on this page. Instead of relying on a long half-life of the drug molecule itself, the formulation traps exenatide inside biodegradable microspheres. After injection, the microspheres slowly degrade and release exenatide over weeks. The label notes that plasma concentrations generally fall below minimal detectable levels about 10 weeks after discontinuation. If you’re transitioning off Bydureon BCise and planning pregnancy, surgery, or a switch to another GLP-1, the timeline is very different from currently marketed weekly GLP-1s.

Renal thresholds. Byetta is not recommended in severe renal impairment or end-stage renal disease (creatinine clearance below 30 mL/min). Bydureon BCise is not recommended when eGFR is below 45 mL/min/1.73 m² or in end-stage renal disease. Both are cleared mostly by the kidneys — unlike modern GLP-1s.

Here is a common pattern after a final weekly GLP-1 injection. Your experience may vary.

The biological explanation is straightforward. GLP-1s act on receptors in the hypothalamus (the brain region that regulates hunger and satiety) and on the gut. As drug concentration drops below the threshold where those receptors are meaningfully activated, normal hunger signaling resumes.

The return is usually gradual rather than sudden. Intensity varies significantly between people. Some describe a sudden return of pre-treatment hunger patterns; others barely notice for weeks. There’s no reliable clinical predictor of how dramatic the return will be for any individual.

The side-effect timeline runs alongside the drug-level timeline but doesn’t perfectly mirror it. Nausea often improves quickly after reducing or stopping a dose — sometimes within days. Gastric slowing effects (feeling full after small amounts, constipation, heartburn) can linger longer because the gut’s motility patterns need time to recalibrate.

Severe or worsening symptoms after stopping warrant a call to your prescriber. Pancreatitis and gallbladder disease are rare but real risks associated with GLP-1 use, and symptoms can overlap with other serious conditions. Don’t dismiss severe abdominal pain as a side effect.

The main anesthesia concern with GLP-1s is delayed gastric emptying, which can increase the risk of aspiration — inhaling stomach contents — during sedation. The primary risk factors are dose, duration, and the type of procedure (full anesthesia vs sedation vs local).

Surgical team protocols vary. Some anesthesia providers still follow the 2023 ASA guidance (hold weekly GLP-1s for 1 week before; hold daily GLP-1s the day of). Others have adopted the 2024 multi-society update, which supports continued use in many patients with appropriate precautions (such as liquid diet before surgery and aspiration risk assessment). Tell every clinician involved — surgeon, anesthesiologist, and primary prescriber.

Endoscopy and colonoscopy have their own considerations. If you’re having an elective upper GI procedure, your gastroenterologist may want you to hold GLP-1s for a period beforehand to reduce residual gastric contents. Ask specifically.

The extended washout periods for semaglutide (2 months) and tirzepatide (1 month) exceed the pharmacokinetic clearance time (5 weeks and 4 weeks, respectively) because they account for the long half-life plus animal reproductive toxicity data plus a margin of safety. These are FDA label recommendations, not suggestions.

If you have type 2 diabetes and are stopping a GLP-1 to plan a pregnancy, you also need a clinician-directed plan for managing blood sugar during the washout period and during pregnancy. Blood sugar management in pregnancy has direct effects on fetal outcomes and is not something to improvise.

The key concern with overlapping GLP-1s is additive side effects — particularly nausea, vomiting, and rapid blood sugar changes in people with diabetes. There is no controlled clinical data on the optimal switching interval between most GLP-1 pairs.

If you’re switching from compounded semaglutide to an FDA-approved product (or vice versa), don’t assume a milligram-for-milligram swap unless your prescriber and pharmacist verify the active ingredient, concentration, route, and delivered dose of the compounded product. Compounding quality varies significantly.

Athletic, military, occupational, and court-ordered panels vary — ask the testing organization specifically what is on the panel. GLP-1s are not substances of abuse, and no evidence suggests they have a performance-enhancing effect, but monitoring programs are updated regularly and what’s on the WADA monitoring list can change.